Citadel Advisors
INKT icon

Citadel Advisors’s MiNK Therapeutics INKT Stock Holding History

Citadel Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,081
Closed -$18.9K – 14820
2024
Q1 		$18.9K Sell
2,081
-2,133
-51% -$19.8K ﹤0.01% 13049
2023
Q4 		$45.3K Buy
+4,214
New +$44K ﹤0.01% 11882
2023
Q3 		– Sell
-5,105
Closed -$107K – 14668
2023
Q2 		$107K Buy
+5,105
New +$102K ﹤0.01% 10829

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's INKT Position: Q2 2024 in Review

Citadel Advisors sold out of MiNK Therapeutics (INKT) in Q2 2024, closing a stake of 2,081 shares — an estimated $18.9K sold.

Citadel Advisors first reported a position in INKT in Q2 2023 and held it in 3 quarters. The position peaked at $107K in Q2 2023. 29 funds tracked by Wall St. Rank hold INKT as of Q2 2024.

  • Citadel Advisors reported no remaining MiNK Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 2,081 MiNK Therapeutics shares in Q2 2024, an estimated $18.9K.
  • Citadel Advisors first reported a position in MiNK Therapeutics in Q2 2023 and held it in 3 quarters.
  • Citadel Advisors's MiNK Therapeutics position peaked at $107K in Q2 2023.
  • 29 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.